Higher blood levels of fibroblast growth factor 23 (FGF23) — a bone-derived hormone — are associated with higher levels of established markers of heart damage…
ATTR-CM
An artificial intelligence (AI) model that analyzes the results of echocardiograms may help predict the likelihood of transthyretin amyloid cardiomyopathy (ATTR-CM) in people…
Researchers have identified a common structure among toxic transthyretin (TTR) clumps, called amyloid fibrils, in heart tissue from people carrying mutations linked to hereditary…
In people with transthyretin amyloid cardiomyopathy (ATTR-CM), the buildup of faulty transthyretin (TTR) protein in the heart may contribute to blood clots that block…
People with transthyretin amyloid cardiomyopathy (ATTR-CM) enrolled in more recent clinical trials show less advanced disease and improved survival compared with those in earlier studies,…
New analyses back the use of the approved therapy Amvuttra (vutrisiran) as an initial treatment for people with transthyretin amyloidosis with cardiomyopathy (ATTR-CM)…
New analyses suggest Attruby (acoramidis) may reduce the risk of outpatient worsening heart failure, with differences seen within 30 days and sustained through 30…
The oral therapy acoramidis has been approved in Brazil, to be sold as Beyonttra, for treating adults with hereditary or wild-type transthyretin amyloid cardiomyopathy…
The U.S. Food and Drug Administration (FDA) has granted fast track designation to coramitug, an experimental treatment in late-stage clinical testing for transthyretin…
A blood test measuring levels of the protein MR-proADM may help predict heart failure events (worsening of symptoms requiring immediate medical care) and death in…
Recent Posts
- EU panel backs approval of generic version of oral heart drug
- Real-world study compares 2 options for amyloidosis treatment
- Taiwan’s summer heat teaches us to live a calm, slow life
- ATTR-CM outcomes differ by sex, but biology may not explain why
- No one in the amyloidosis community needs to go it alone